ObsEva SA – NASDAQ:OBSV
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
ObsEva SA stock price monthly change
-41.68%
month
ObsEva SA stock price quarterly change
-30.66%
quarter
ObsEva SA stock price yearly change
-92.27%
year
ObsEva SA key metrics
Market Cap | 10.99M |
Enterprise value | 3.97M |
P/E | -0.13 |
EV/Sales | 0.20 |
EV/EBITDA | -0.06 |
Price/Sales | 0.47 |
Price/Book | 1.10 |
PEG ratio | N/A |
EPS | -0.85 |
Revenue | N/A |
EBITDA | -12.65M |
Income | -29.87M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -379.27% |
Oper. margin | -293.79% |
Gross margin | 0% |
EBIT margin | -293.79% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeObsEva SA stock price history
ObsEva SA stock forecast
ObsEva SA financial statements
| Mar 2022 | 0 | -11.80M | |
|---|---|---|---|
| Jun 2022 | 0 | -32.79M | |
| Sep 2022 | 0 | -12.05M | |
| Dec 2022 | 19.63M | 26.77M | 136.36% |
| 2022-12-01 | -0.08 | -0.12562 |
|---|---|---|
| 2023-03-06 | -0.06 | -0.26 |
| Mar 2022 | 89144000 | 61.17M | 68.63% |
|---|---|---|---|
| Jun 2022 | 54184000 | 56.28M | 103.88% |
| Sep 2022 | 16807000 | 19.95M | 118.74% |
| Dec 2022 | 16544000 | 8.06M | 48.72% |
| Mar 2022 | -15.25M | 5.68M | 12.19M |
|---|---|---|---|
| Jun 2022 | -10.72M | -11K | -1.16M |
| Sep 2022 | -5.09M | 0 | -30.34M |
| Dec 2022 | 7.92M | -5.67M | 2.50M |
ObsEva SA alternative data
| Aug 2023 | 48 |
|---|---|
| Sep 2023 | 48 |
| Oct 2023 | 48 |
| Nov 2023 | 48 |
| Dec 2023 | 48 |
| Jan 2024 | 48 |
| Feb 2024 | 48 |
| Mar 2024 | 48 |
| Apr 2024 | 48 |
| May 2024 | 48 |
| Jun 2024 | 48 |
| Jul 2024 | 48 |
ObsEva SA other data
36.29%
-2.48%
of OBSV is owned by hedge funds
15.80M
-1.07M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2023 | 4000000 | 0 |
| Apr 2023 | 4000000 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2022 17 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2019 5 Mar 2020 | Q4 2019 Earnings Call Transcript |
| Q2 2019 12 Aug 2019 | Q2 2019 Earnings Call Transcript |
| Q1 2019 13 May 2019 | Q1 2019 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Brian O'Callaghan (1969) Chief Executive Officer & Director | $4,290,000 |
Dr. Ernest Loumaye (1952) Co-Founder & Director | $1,000,000 |
-
When is ObsEva SA's next earnings date?
Unfortunately, ObsEva SA's (OBSV) next earnings date is currently unknown.
-
Does ObsEva SA pay dividends?
No, ObsEva SA does not pay dividends.
-
How much money does ObsEva SA make?
ObsEva SA has a market capitalization of 10.99M. ObsEva SA made a loss 29.88M US dollars in net income (profit) last year or -$0.26 on an earnings per share basis.
-
What is ObsEva SA's stock symbol?
ObsEva SA is traded on the NASDAQ under the ticker symbol "OBSV".
-
What is ObsEva SA's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ObsEva SA?
Shares of ObsEva SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ObsEva SA's key executives?
ObsEva SA's management team includes the following people:
- Mr. Brian O'Callaghan Chief Executive Officer & Director(age: 56, pay: $4,290,000)
- Dr. Ernest Loumaye Co-Founder & Director(age: 73, pay: $1,000,000)
-
Is ObsEva SA founder-led company?
Yes, ObsEva SA is a company led by its founder Dr. Ernest Loumaye.
-
How many employees does ObsEva SA have?
As Jul 2024, ObsEva SA employs 48 workers.
-
When ObsEva SA went public?
ObsEva SA is publicly traded company for more then 7 years since IPO on 13 Jul 2018.
-
What is ObsEva SA's official website?
The official website for ObsEva SA is obseva.com.
-
How can i contact ObsEva SA?
ObsEva SA can be reached via phone at +41 22 552 38 40.
ObsEva SA company profile:
ObsEva SA
obseva.comExchange:
NASDAQ
Full time employees:
48
Industry:
Biotechnology
Sector:
Healthcare
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Chemin des Aulx, 12
Geneva, 1228
Geneva, 1228
CIK: 0001685316
ISIN: CH0346177709
CUSIP: H5861P103
